In 2014, the ACR launched the Rheumatology Informatics System for Effectiveness (RISE), a national electronic health record (EHR)-enabled registry. The goal: To help participating rheumatologists and practices leverage the new wave of big data created by the use of EHR, advance research and improve overall quality of care. A new analysis examines the RISE structure and the initial patient data collected by the registry…
Sarilumab Approval Stalled; Piclidenoson Promising for Psoriasis
Due to manufacturing deficiencies found during a routine inspection by the FDA, approval of sarilumab for treating RA has slowed until facility issues are resolved…
Accelerating Medicines Partnership Advances Research for Autoimmune Diseases
Advancing the understanding of autoimmune diseases has implications for precision medicine, according to Robert Carter, MD, of the NIH. Research funded through the NIH’s Accelerating Medicines Partnership has the potential to develop better biomarkers and clinical trials for lupus and RA, paving the way for more personalized treatment…
Metabolomic Profiles: A Biomarker for the Biological Treatment of RA
A recent study suggests that metabolites may be a biomarker for disease activity in patients with rheumatoid arthritis (RA). For the first time, researchers identified serum metabolomic profiles and 16 clinical parameters that serve as a reasonably predictive model for a patient’s therapeutic response to biological treatment of RA, specifically TNF-α inhibitor therapy…
Statins & the Risk of RA
Statins have anti-inflammatory/immunomodulatory effects that may be useful in preventing rheumatoid arthritis (RA), but previous observational studies about the risk of RA with statin use yielded conflicting results. In this large population-based study, high-intensity statin treatment was associated with a 23% reduced risk of RA when compared with low-intensity statin treatment. This is the largest study on the association of statins with RA risk to date, and the first to assess the effect of relative statin strength…
Do Fatty Acids Underlie Rheumatoid Arthritis Pathology?
According to a new study, patients with aggressive rheumatoid arthritis (RA) have lower levels of non-esterified fatty acids, which coincide with an enhanced Th1 response. Researchers suggest that lower EPA and DHA at the onset of RA may exacerbate inflammation, and fatty acids may become a novel therapeutic target for the disease…
Gout Treatment & Care Remain Suboptimal
A recent analysis compared the care of patients with RA with that received by patients with gout, finding that hospitalization and costs for patients with gout have increased, but both are decreasing for patients with RA. Unlike RA, significant advances in treatment have not been made for gout, despite its increasing prevalence, and patients may land in the hospital unnecessarily…
The Real Story on RA: Survey Finds Communication Gaps Between Physicians & Patients with RA
Survey results released earlier this year found that communication difficulties exist between patients and their rheumatologists for many reasons—possibly resulting in more disease activity despite advances in RA treatments. Here are tips for communicating with your patients and helping them be more proactive in their care…
Patients with Active RA Have Higher Drug Efflux Transporter Activity
New research examined the peripheral blood in patients with rheumatoid arthritis to investigate the association between disease activity, treatment and the functional activity of ABCB1 and ABCG2 drug efflux transporters. Results showed that transporter activity may correlate with increased disease activity and persist unrelated to treatment for as long as six months in some patients…
Mesoblast Cell Treatment Shows Promise in Rheumatoid Arthritis
(Reuters)—Mesoblast Ltd. on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial. Treatment with the Australian company’s mesenchymal precursor cell (MPC) product, MPC-300-IV, was deemed well tolerated with…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 30
- Next Page »